CACF Capital Innovation
Innovation investment company of Crédit Agricole Centre France
Also known as SAS CACF Capital Innovation
Clermont-Ferrand investment company (SAS, 2018) at the head office of Crédit Agricole Centre France; took part in Brenus Pharma’s €22M Series A in 2024.
“CACF” here is Crédit Agricole Centre France (Clermont-Ferrand), not Crédit Agricole Consumer Finance.
- HEADQUARTERS
- Clermont-Ferrand, France
- FOUNDED
- —
- AUM
- —
- OUTSIDE CAPITAL
- No — own capital only
- TEAM LISTED
- —
Focus
- STAGES
- Series A
- SECTORS
- Biotech & Life Sciences
- GEOGRAPHY
- —
Overview
CACF Capital Innovation is a simplified joint-stock company created in 2018 and registered at 1 avenue de la Libération, Clermont-Ferrand, the head office of the regional bank Crédit Agricole Centre France, whose registered short name is CACF. In September 2024 CACF Capital Innovation invested in the €22M Series A of Brenus Pharma, a clinical-stage cancer-vaccine biotech, alongside Angelor, Crédit Agricole Création and UI Investissement.
PORTFOLIO (1)
- Brenus PharmaBiotech & Life Sciences · since 2024
Frequently asked questions
CACF Capital Innovation is a corporate venture arm based in Clermont-Ferrand, France.
Yes. CACF Capital Innovation invests its own capital in private companies.
CACF Capital Innovation invests at Series A stage in Biotech & Life Sciences.
CACF Capital Innovation's investments include Brenus Pharma.
The most recent publicly reported investment by CACF Capital Innovation is Brenus Pharma (€22M Series A), announced in Sep 2024.
No. CACF Capital Innovation invests its own capital and does not raise money from outside investors.